Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Unknown 1

Sponsor Class

OTHER 4NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Rectal Neoplasms 2Leukemia 2Colonic Neoplasms 2Breast Neoplasms 2Oligodendroglioma 1Lung Neoplasms 1Leukemia, Lymphocytic, Chronic, B-Cell 1Colorectal Neoplasms 1Central Nervous System Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Intraductal, Noninfiltrating 1Astrocytoma 1

Interventions

Carboplatin 50Paclitaxel 48Cisplatin 39Gemcitabine 31Erlotinib Hydrochloride 30Radiotherapy 28Docetaxel 24Taxes 21Specimen Handling 20Magnetic Resonance Spectroscopy 20Vinorelbine 16Pemetrexed 12Etoposide 12Bevacizumab 12Radiation 10Gefitinib 10aldesleukin 8Platinum 8Bortezomib 8Biopsy 8Vinblastine 7Azacitidine 71,2-diaminocyclohexaneplatinum II citrate 7pembrolizumab 6atezolizumab 6Observation 6Immunoglobulin G 6Disulfides 6Cyclophosphamide 6Chemotherapy, Adjuvant 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Carcinoma, Non-Small-Cell Lung × In Situ Hybridization, Fluorescence × Clear all
NCT00989690 2013-08-12

Study of Blood and Tissue Samples in Predicting Response to Second-Line Therapy Using Erlotinib Hydrochloride or Chemotherapy in Patients With Advanced Non-Small Cell Lung Cancer

National Cancer Institute (NCI)

Phase 3 Unknown
275 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡